CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 77 enrolled
Drug / intervention
Fluzone® +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03028974
NCT03028974Phase 4Completed
CompareCT.gov

Adaptive and Innate Immunity, Memory and Repertoire in Vaccination and Infection

Stanford University·interventional·Posted Jan 23, 2017·Updated Dec 14, 2018

In Brief

A Phase 4 clinical trial evaluating Fluzone® and FluMist® for Influenza. Completed, enrolled 77 participants across 1 site.

Detailed Summary

The purpose of the study is to get a better understanding of the natural and adaptive immune response to the flu virus and to compare the immune cell responses to FDA-licensed flu vaccines in nasal mucosal cells and in blood.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 23, 2017
Enrollment StartSep 17, 2014
Primary CompletionNov 20, 2017
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 9.4 years ago

Interventions

Fluzone®biological

Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine

FluMist®biological

FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray